Klotho Neurosciences Holds Inaugural Conference on Neurodegenerative Therapies

Klotho Neurosciences Hosts Inaugural Conference on Future Therapies

Klotho Neurosciences, Inc. (NASDAQ: KLTO) is stepping into the spotlight as its CEO, Dr. Joseph Sinkule, gears up for the company's first-ever conference focused on Klotho-based therapeutics aimed at tackling neurodegenerative diseases. Scheduled for September 15-16, 2025, this groundbreaking event will take place at the UC-Irvine Beal Applied Innovation Center in Irvine, California.

The conference's agenda promises to be enlightening, with key presentations from the company's leading scientific advisors and inventors, Dr. Miguel Chillon and Dr. Assumpcio Bosch. They will unveil their latest research findings on the innovative Klotho gene therapy targeting conditions such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease, and advancements in promoting longevity.

Dr. Sinkule's presence at the conference will also present a unique opportunity for investors and potential partners to engage in meaningful discussions about the future direction of Klotho Neurosciences. Interested parties are invited to reach out via email for further inquiries.

About Klotho Neurosciences

Klotho Neurosciences has a mission to develop cutting-edge therapies that modify diseases and improve the conditions of patients suffering from neurodegenerative and age-related disorders. By leveraging a patented form of the human